StockWatch
·

Research Reports

21 Oct 2026
DRAGARWQAGARWALEYE

Dr Agarwal's Eye Hospital merges into Health Care Nov 1; the 23-for-2 swap was worth ~6% more at Oct 19 closes

amalgamation · NCLT · record date

Research5 minPharma & Healthcare
PPLPHARMAPiramal Pharma Ltd

Momentum or Margin Trap? The Real Test for Piramal's Growth Narrative

earnings · EBITDA margin · Bayer distribution

Result previewQ2 FY273 minPharma & Healthcare
CIPLACIPLA LTD.

Can margin momentum stabilize after Q1's steep profit decline?

CIPLA Q2 earnings · Revlimid Lanreotide headwinds · EBITDA margin recovery

Result previewQ2 FY273 minPharma & Healthcare
20 Oct 2026
VENUSREMVENUS REMEDIES LTD.

Specialty Pharma Momentum — Growth and Margin Expansion on Track

specialty pharma · margin expansion · international growth

Result previewQ2 FY273 minPharma & Healthcare
MANKINDMankind Pharma Ltd

Margins hold the line as Mankind navigates acquisition & consolidation

margin defense · FY27 guidance · ACTx acquisition

Result previewQ2 FY273 minPharma & Healthcare
17 Oct 2026
BAJAJHCAREBajaj Healthcare Ltd

Bajaj Healthcare Q2 FY27: standalone revenue +19% YoY to ₹176 Cr, OPM dips to 17.7%

pharmaceuticals · active pharmaceutical ingredients · margin compression

ResultsQ2 FY273 minPharma & Healthcare
JLHLJupiter Life Line Hospitals Ltd

The Ramp Test: Dombivli Occupancy Will Define the Quarter

expansion drag · margin compression · Dombivli ramp-up

Result previewQ2 FY273 minPharma & Healthcare
DRREDDYDR.REDDY'S LABORATORIES LTD.

Margin recovery test: Can Dr. Reddy's arrest the slide?

generics pricing · EBITDA margins · US market

Result previewQ2 FY273 minPharma & Healthcare
TORNTPHARMTORRENT PHARMACEUTICALS LTD.

Merger momentum & margin accretion on deck — first full quarter post-JB integration

JB Chemicals merger · integration accretion · margin expansion

Result previewQ2 FY273 minPharma & Healthcare
16 Oct 2026
SOLARASolara Active Pharma Sciences Ltd

Solara Q2 FY27: Consolidated Swings to ₹28.5 Cr Profit, Revenue +33% YoY, Margins Expand

turnaround · margin expansion · api manufacturing

ResultsQ2 FY273 minPharma & Healthcare
AKUMSAkums Drugs and Pharmaceuticals Ltd

NPPA demands ₹52.75 Cr over Lanol pricing; Akums says marketer Hetero bears prime responsibility

NPPA · DPCO 2013 · demand notice

Research4 minPharma & Healthcare
MANKINDMankind Pharma Ltd

Mankind Pharma to buy 70% of Belgian CAR-T developer ACTx for EUR 48 million — its entry into cell therapy

CAR-T therapy · cross-border acquisition · Armed Cell Therapeutics

Research5 minPharma & Healthcare
15 Oct 2026
BIOCONBIOCON LTD.

Biocon–Genentech settlement fixes Pebrilzo's earliest launches: EU/UK in Q1 2027, the US in Q3 2028

biosimilar · pertuzumab · pebrilzo

Research4 minPharma & Healthcare
13 Oct 2026
ZYDUSLIFEZydus Lifesciences Ltd

USFDA accepts the first publicly announced Keytruda biosimilar for review; Zydus holds the US and Canada rights

biosimilar · pembrolizumab · FYB206

ResearchDeep dive6 minPharma & Healthcare
11 Oct 2026
SOLARASolara Active Pharma Sciences Ltd

Solara Q2 Preview: Momentum Intact but Commodity Headwinds to Watch

earnings preview · Q2 FY27 · pharma actives

Result previewQ2 FY273 minPharma & Healthcare
05 Oct 2026
HNILHimalaya Nutravedics India Ltd

Himalaya Wellness and Himalaya Global Holdings sue Himalaya Nutravedics over its name; the company will contest

trademark · commercial suit · regulation 30

Research4 minPharma & Healthcare
03 Oct 2026
SAIPARENTSai Parenterals Ltd

Sai Parenterals' monitoring agency flags ₹23.87 Cr of IPO-proceeds deviations the company reported as nil

IPO proceeds · monitoring agency report · India Ratings

ResearchDeep dive6 minPharma & Healthcare
30 Sept 2026
SANOFISanofi India Ltd

Sanofi India: pre-disclosed ₹1,068 Cr inter-se transfer moves 15.2% from Hoechst to Sanofi Healthcare India

inter-se transfer · promoter shareholding · block deal

Research4 minPharma & Healthcare
29 Sept 2026
NATCOPHARMNATCO PHARMA LTD.

Natco Pharma's ₹1,279 Cr rights issue is final: 2 shares for every 21 at ₹750, record date October 1

rights issue · letter of offer · record date

Research4 minPharma & Healthcare
ANURASAnupam Rasayan India Ltd

Anupam Rasayan completes the Bliss GVS purchase: ₹299 a share for 48.2%, funded mostly by outside investors

Anupam Rasayan · Bliss GVS Pharma · acquisition

ResearchDeep dive6 minMetals & Mining
22 Sept 2026
THYROCAREThyrocare Technologies Ltd

Thyrocare approves ₹141.4 Cr sale of Nueclear radiology arm to refocus capital on core pathology

Thyrocare · Nueclear Healthcare · Trovera Healthcare

ResearchDeep dive6 minPharma & Healthcare
18 Sept 2026
GUJTHEMGUJARAT THEMIS BIOSYN LTD.

Gujarat Themis completes the MicroBiopharm Japan acquisition, with ₹1,220 Cr routed into its Japan arm

acquisition · CDMO · fermentation

ResearchDeep dive6 minPharma & Healthcare
16 Sept 2026
GRANULESGRANULES INDIA LTD.-$

Granules' ₹1,093 Cr warrant balance is paid — funded by a ₹1,509 Cr promoter share sale four days earlier

preferential issue · warrants · block deal

ResearchDeep dive6 minPharma & Healthcare
15 Sept 2026
NEULANDLABNEULAND LABORATORIES LTD.

Neuland's first peptide module is operational; a second of up to 18,000L waits on customer specs

peptide manufacturing · CDMO · capacity expansion

ResearchDeep dive6 minPharma & Healthcare
14 Sept 2026
YATHARTHYatharth Hospital & Trauma Care Services Ltd

Yatharth group gets ₹43.8 Cr in final tax demands plus ₹15.9 Cr interest; appeals next, no provision booked

income tax · assessment orders · appeals

Research4 minPharma & Healthcare
26 Aug 2026
PARKHOSPSPark Medi World Ltd

Prayagraj's Healthcare Inflection—When ₹200 Crore PPP Unlocks Tier-2 Scale

Public-Private Partnership · healthcare infrastructure · Prayagraj

ResearchDeep dive5 minPharma & Healthcare
CYIENTCyient Limited

When Indian IT Pivots to CDMO: Cyient's Tao Digital Wager on AI-Enabled Drug Manufacturing

CDMO · AI-enabled manufacturing · US acquisition

ResearchDeep dive5 minPharma & Healthcare
20 Aug 2026
KIMSKrishna Institute of Medical Sciences Ltd

KIMS' Asset-Light Call Option—When O&M Upside Meets a Hospital Shortage

asset-light expansion · O&M model · call option

ResearchDeep dive5 minPharma & Healthcare
GLENMARKGLENMARK PHARMACEUTICALS LTD.

Glenmark's FDA Nasal Spray Entry: The ₹295 Crore Opportunity

FDA approval · nasal spray · generics

ResearchDeep dive6 minPharma & Healthcare
THYROCAREThyrocare Technologies Ltd

Thyrocare's ₹1,700 Crore Debt Victory: What the Share Release Signals

debt repayment · pledge release · capital structure

ResearchDeep dive5 minPharma & Healthcare